In a recent publication, the authors reported a liquid chromatography-mass spectrometry-time of flight procedure for the simultaneous analysis of 22 benzodiazepines in urine specimens. In this report, the list of benzodiazepines that could be analyzed was expanded to 35 benzodiazepines, and data for the additional 13 analytes are presented. The analysis focused on the most commonly prescribed benzodiazepines and/or their metabolites. Using this method, the limit of quantitation for all benzodiazepines tested ranged from 0.1 to 10 ng/mL, and the limit of determination range was 0.03 to 3.0 ng/mL. The method was used for the analysis of 111 forensic/clinical samples previously tested for benzodiazepines by immunoassays (81 positives and 30 negatives). All immunoassay positive specimens were confirmed by this procedure for one or more analytes. However, only 12 out of the 35 benzodiazepines analyzed were detected in these specimens.
Introduction
Benzodiazepines are a class of clinically important drugs with therapeutic activities which cover a wide range of indications, thus making them useful in the treatment of stress and other disorders including panic and sleep disorders and seizures (1, 2) . Some benzodiazepines are also used to induce sedation before certain medical procedures including dental work, endoscopies, among others. Over 2000 different benzodiazepines have been synthesized (1, 2) , making them one of the most diverse classes of therapeutic agents.
In recent years, liquid chromatography-mass spectrometry (LC-MS) has provided a useful procedure for the analysis of organic compounds. There are many reviews for the use of highperformance LC in combination with MS as the detection method (3) (4) (5) (6) (7) , and others in which photodiode array (8, 9) or capillary electrophoresis (10) was used.
In previous publications (11, 12) , the authors of the present study reported on a newly developed procedure for the simultaneous analysis of 22 different benzodiazepines using LC coupled with MS-time of flight (TOF).
The present study expanded on the LC-MS-TOF procedure to include an additional 13 benzodiazepines, namely: medazepam, halazepam, prazepam, clordiazepoxide, clobazam, flurazepam, α-OH midazolam, clonazepam, N-ethylnordiazepam, demoxepam, chlorazepate, desalkylflurazepam, and 7-aminonitrazepam, for a total of 35 benzodiazepines. The sensitivity of the new LC-MS-TOF procedure was such that the limit of detection ranged from 0.03 to 1.0 ng/mL for all benzodiazepines tested. For those benzodiazepines for which the Society of Forensic Toxicologists (SOFT) Drug Facilitated Sexual Assault (DFSA) Committee has recommended a maximum detection limit, this procedure offers a detection limit 5-10 times lower.
The procedure was used for the analysis of 111 forensic/clinical urine specimens previously tested for benzodiazepines by immunoassay (81 positives and 30 negatives). β-Glusulase (glucuronidase~90,000 units/mL and sulfatasẽ 10,000 units/mL) was purchased from PerkinElmer (Shelton, CT).
Chemicals and reagents
High-performance liquid chromatography (HPLC)-grade chloroform and isopropyl alcohol were obtained from VWR (West Chester, PA). Sodium carbonate, HCl, acetonitrile, and glacial acetic acid were purchased from Fisher Scientific (Fair Lawn, NJ). Water for the LC mobile phase was purified in a Milli-Q system (Millipore, Bedford, MA).
Specimens
The urine samples used for this study were not part of a clinical trial but were samples that were previously analyzed as part of routine submission to the laboratory for analysis. These samples were collected over a period of five years and kept frozen (-20°C) until analyzed.
Validation Experiments
The same procedures outlined in previous publications (11, 12) were used for the preparation of calibration curves, hydrolysis, and extraction of the urine specimens as well as instrumentation and chromatographic conditions. Briefly, urine specimens (1-mL aliquots) were spiked with the internal standards, buffered (1 mL sodium acetate buffer, pH 5.2), and then enzyme hydrolyzed (10,000 units β-glusulase) at 37°C for 4 h. The hydrolyzed material was then basified (1 mL 1.5 M sodium carbonate buffer) and then extracted (4 mL chloroform/isopropanol, 9:1). The organic extract was then evaporated and the residue dissolved in 100 µL MeOH for LC-MS analysis.
The LC used (Agilent series 1100, Agilent Technologies, Palo Alto, CA) included the following modular components: quaternary pump, a vacuum solvent microdegasser, an autosampler with 100-well tray, and an inline diode-array detector. The MS analysis was performed on an LC-MSD-TOF (model #G1969A) equipped with an electrospray ionization source. The LC-MSD-TOF was calibrated using the Agilent tune mix. All acquisitions were performed under positive ionization mode with a capillary voltage of 3500 V. Nitrogen was used as nebulizer gas (30 psig) as well as drying gas at 10 L/min at drying gas temperature of 325°C. The voltages of the photo multiplier tube, fragmentor, and skimmer were set at 850 V, 100 V, and 60 V, respectively. Full scan mass spectra were acquired from m/z 200 to 900. Data acquisition and processing were done using the Analyst™ QS software (Agilent). Separation was achieved on a Luna C 8 (2) column (100 × 4.6 mm-i.d., 3-µm particle size, Phenomenex, Torrance, CA). The column was equipped with a guard column (Supelco, Bellefonte, PA). The mobile phase consisted of a mixture of water (0.1% acetic acid) (A) and acetonitrile (0.1% acetic acid) (B) ( Table II) . At a flow rate of 0.3 mL/min, a gradient elution was set up as follows: 73% A/27% B to 40% A/60% B at 50 min, then 100% B for 5 min followed by a 5 min wash with 100% acetonitrile. The total run time for analysis was 55 min. The injection volume was 10 µL.
Results and Discussion
The LC-MS-TOF method previously described for the analysis of 22 different benzodiazepines (11, 12) was expanded to include a total of 35 analytes in the same run. Table I shows a list of the additional 13 analytes and the validation data associated with each benzodiazepine, which include linearity, limit of quantitation (LOQ), and limit of detection (LOD).
The calibration curves for all analytes were linear (r 2 > 0.999) for all compounds over a range of 10-250 ng/mL (except N-ethylnordiazepam, where the linear range was 10-100 ng/mL).
This method was based on accurate mass measurement using the TOF-MS, the LOD was defined as the lower limit where analytes could be detected with acceptable mass value for the pseudo molecular ion but the quantification was not Figure 8 . Selected ion chromatograms and mass spectra of benzodiazepines identified in urine sample #CC384 (see Table III for concentrations).
Figure 9.
Selected ion chromatograms and mass spectra benzodiazepines identified in urine sample #CC390 (see Table III for concentrations). Table III for concentrations).
necessarily within ± 20% of the nominal. This lower limit was determined as having a signal-to-noise ratio of 3:1. The LOQ was the lowest concentration having accurate mass and at which the analytes could be quantified within ± 20% of the nominal value. This limit was determined as the concentration having a signal to noise ratio of 10:1. The method had excellent sensitivity for all analytes where the LOD was ≤ 1 ng/mL for most analytes (9 out of 13).
The sensitivity of the method was highest for N-ethylnordiazepam where the LOD and LOQ were 0.03 and 0.1 ng/mL, respectively, and lowest for chlorazepate (LOD 1.0 and LOQ 5.0 ng/mL).
Comparing the sensitivity of the method relative to the requirements recommended by the SOFT committee on DFSA, the method meets or far exceeds those requirements. For many of the drugs analyzed, the method's sensitivity is 5-10 times greater than the recommended levels. Figures 1-6 show chromatograms covering the 13 additional benzodiazepines incorporated in the method along with their internal standards and their mass spectra. All standards' chromatograms and spectra were from extracted urine spiked at 10 ng/mL, except for 7-aminonitrazepam (25 ng/mL). The data show good peak resolution, without interferences, peak symmetry, and accurate molecular ion peaks.
The method (with all 35 benzodiazepines) was used to analyze 111 forensic/clinical specimens (81 positives and 30 negatives). All negative specimens were found to be negative for all benzodiazepines (below LOD level). The 81 positive specimens, however, were found to be positive for one or more benzodiazepines. Table III shows a list of the positive specimens and the concentration (ng/mL) of each compound identified.
The data in Table III show that among the 35 benzodiazepines included in the method, only 12 were identified in any of the specimens. These 12 analytes are nordiazepam, oxazepam, diazepam, temazepam, lorazepam, alprazolam, α-OHalprazolam, demoxepam, chlordiazepoxide, 7-aminoclonazepam, lormetazepam, and clonazepam. These represent the most widely prescribed benzodiazepines and/or their metabolites.
Figures 7-10 show representative chromatograms from the analysis of four of the positive specimens showing the benzodiazepines and their mass spectra, identified in those specimens.
Conclusions
A sensitive and reliable method was developed for the analysis of 35 different benzodiazepines and/or metabolites in urine. The method was used for the analysis of 81 specimens that screened positive for benzodiazepines and all specimens were confirmed for one or more analytes. In all, only 12 benzodiazepines or metabolites were identified in these samples. These compounds cover the most commonly prescribed benzodiazepines in the United States, where > 95% of the prescriptions written for benzodiazepines are for one of these (13) . The method is applicable for the analysis of specimens in forensic situations (such as DFSA cases) where the identity of the benzodiazepine involved is required, and the sensitivity of the method makes it useful in extending the detection time.
